Gentamicin Protection Assay to Determine the Number of Intracellular Bacteria during Infection of Human TC7 Intestinal Epithelial Cells by Shigella flexneri

Gentamicin Protection Assay to Determine the Number of Intracellular Bacteria during Infection of Human TC7 Intestinal Epithelial Cells by Shigella flexneri

Shigella flexneri is an intracellular bacterial pathogen that positive aspects entry to the intestine epithelium utilizing a specialised Type III Secretion System (T3SS). Various determinants mediating this invasive an infection have been experimentally verified utilizing the classical gentamicin safety assay introduced right here. In this assay epithelial cell strains are contaminated by micro organism in vitro and the extracellular micro organism are killed by gentamicin. The internalized micro organism, that are shielded from the bactericidal motion of gentamicin, are recovered by lysing the epithelial cells and enumerated by figuring out the colonies fashioned on strong medium.

Various methods primarily based on gentle microscopy, reminiscent of immunofluorescence and micro organism expressing fluorescent proteins, are additionally used for finding out intracellular micro organism. However, these methods should not solely labor intensive and require refined tools, however principally are additionally not quantitative. Despite being a straightforward quantitative technique to research invasiveness of micro organism, the gentamicin safety assay can’t distinguish between the survival and multiplication of the internalized micro organism over longer incubation durations.

To alleviate the problems created by multiplication and dissemination of internalized micro organism, complementary assays like plaque formation assays are required. This protocol presents a straightforward and cost-effective technique to decide the invasiveness and the capability to set up an an infection of Shigella below totally different circumstances. Automatic and visible interpretation of outcome bands have been additionally in contrast for the immunochromatography-based BinaxNOW and ImmuView UATs.

Urinary antigen exams (UATs) are sometimes used to diagnose Legionnaires’ illness as they’re speedy and simple to carry out on readily obtainable urine samples with out the want for specialised abilities in contrast to standard strategies. Recently developed automated readers for UATs could present goal outcomes interpretation, particularly in instances of weak outcome bands. Using 53 outlined affected person urine samples, we evaluated the efficiency of the BinaxNOW Legionella Antigen Card (Abbott), ImmuView S. pneumoniae and Legionella (SSI Diagnostica), STANDARD F Legionella Ag FIA (SD Biosensor), and Sofia Legionella FIA (Quidel) concurrently with their respective automated readers.

SARS-CoV-2 lateral circulation assays for attainable use in nationwide covid-19 seroprevalence surveys (React 2): diagnostic accuracy research

ensitivity analyses have been carried out on sera saved from 320 earlier contributors in the React 2 programme with confirmed earlier extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) an infection. Specificity analyses have been carried out on 1000 prepandemic serum samples. 100 new contributors with confirmed earlier SARS-CoV-2 an infection attended research clinics for finger prick testing.  Laboratory sensitivity and specificity analyses have been carried out for seven LFIAs on a minimal of 200 serum samples from contributors with confirmed SARS-CoV-2 an infection and 500 prepandemic serum samples, respectively.
Three LFIAs have been discovered to have a laboratory sensitivity superior to the finger prick sensitivity of the LFIA presently utilized in React 2 seroprevalence research (84%). These LFIAs have been then additional evaluated by way of finger prick testing on contributors with confirmed earlier SARS-CoV-2 an infection: two LFIAs (Surescreen, Panbio) have been evaluated in clinics in June-July 2020 and the third LFIA (AbC-19) in September 2020. A spike protein enzyme linked immunoassay and hybrid double antigen binding assay have been used as laboratory reference requirements.
The accuracy of LFIAs in detecting immunoglobulin G (IgG) antibodies to SARS-CoV-2 in contrast with two reference requirements. The sensitivity and specificity of seven new LFIAs that have been analysed utilizing sera diverse from 69% to 100%, and from 98.6% to 100%, respectively (in contrast with the two reference requirements). Sensitivity on finger prick testing was 77% (95% confidence interval 61.4% to 88.2%) for Panbio, 86% (72.7% to 94.8%) for Surescreen, and 69% (53.8% to 81.3%) for AbC-19 in contrast with the reference requirements. Sensitivity for sera from matched medical samples carried out on AbC-19 was considerably larger with serum than finger prick at 92% (80.0% to 97.7%, P=0.01). Antibody titres diverse significantly amongst cohorts. The numbers of constructive samples recognized by finger prick in the lowest antibody titre quarter diverse amongst LFIAs.
Gentamicin Protection Assay to Determine the Number of Intracellular Bacteria during Infection of Human TC7 Intestinal Epithelial Cells by Shigella flexneri

Establishment of Novel Protein Interaction Assays between Sin3 and REST Using Surface Plasmon Resonance and Time-Resolved Fluorescence Energy Transfer

Repressor element-1 (RE-1) or neural restrictive silencer component (NRSE) certain with a zinc finger transcription repressor, RE-1 silencing transcription issue (REST, also called neural restrictive silencer issue, NRSF) has been recognized as a basic repressor component in lots of genes, together with neuronal genes. Genes regulated by REST/NRSF regulate multifaceted neuronal phenotypes, and their defects in the equipment trigger neuropathies, issues of neuron exercise), autism and so forth. In REST repressions, the N-terminal repressor area recruits Sin3B by way of its paired amphipathic helix 1 (PAH1) area, which performs an necessary function as a scaffold for histone deacetylase 1 and a pair of. This equipment has a important function in sustaining neuronal robustness.

Acetylcholinesterase Activity Assay Kit - 100 Assays

AR4001-unit unit
EUR 317

Citrulline Fluorometric Assay Kit

K2002-100
EUR 620

Glutathione Fluorometric Assay Kit

K251-100
EUR 479

Glucose Fluorometric Assay Kit

K2221-100 100 assays
EUR 557

Glutathione Fluorometric Assay Kit

K2098-100 100 assays
EUR 502

Lactate Fluorometric Assay Kit

K2140-100 100 assays
EUR 641

Phosphate Assay Kit (Fluorometric)

K2076-100 100 assays
EUR 363

Calcium Assay Kit (Fluorometric)

K409-100
EUR 479

Arginine Assay Kit (Fluorometric)

K384-100
EUR 566

Histamine Assay Kit (Fluorometric)

K386-100
EUR 533

Methionine Assay Kit (Fluorometric)

K442-100
EUR 664

Phosphate Assay Kit (Fluorometric)

K420-100
EUR 349

Zinc Assay Kit (Fluorometric)

K428-100
EUR 523

Adenosine Assay Kit (Fluorometric)

K327-100
EUR 805

Homocysteine Assay Kit (Fluorometric)

K531-100
EUR 648

Tryptophan Assay Kit (Fluorometric)

K557-100
EUR 642

Cysteine Assay Kit (Fluorometric)

K558-100
EUR 561

Phosphatidylserine Assay Kit (Fluorometric)

K565-100
EUR 620

Phenylalanine Fluorometric Assay Kit

K572-100
EUR 479

Glycine Assay Kit (Fluorometric)

K589-100
EUR 691

Phosphatidylglycerol Assay Kit (Fluorometric)

K488-100
EUR 566

Phosphatidylethanolamine Assay Kit (Fluorometric)

K499-100
EUR 631

Ornithine Assay Kit (Fluorometric)

K939-100
EUR 588

Cardiolipin Assay Kit (Fluorometric)

K944-100
EUR 729

Inosine Fluorometric Assay Kit

K712-100
EUR 533

Caspase-12 Fluorometric Assay Kit

K139-100
EUR 501

Caspase-10 Fluorometric Assay Kit

K124-100
EUR 441

Caspase-4 Fluorometric Assay Kit

K126-100
EUR 468

Caspase-3 Fluorometric Assay Kit

K2007-100 100 assays
EUR 474

Caspase-1 Fluorometric Assay Kit

K2010-100 100 assays
EUR 474

Caspase-8 Fluorometric Assay Kit

K2012-100 100 assays
EUR 474

Caspase-6 Fluorometric Assay Kit

K2014-100 100 assays
EUR 474

Caspase-2 Fluorometric Assay Kit

K2016-100 100 assays
EUR 502

Caspase-9 Fluorometric Assay Kit

K2018-100 100 assays
EUR 502

Acetyl-CoA Fluorometric Assay Kit

K2028-100 100 assays
EUR 544

Caspase-12 Fluorometric Assay Kit

K2150-100 100 assays
EUR 529

DPP4 Activity Fluorometric Assay Kit

K2178-100 100 assays
EUR 557

Caspase-5 Fluorometric Assay Kit

K2195-100 100 assays
EUR 502

Caspase-4 Fluorometric Assay Kit

K2198-100 100 assays
EUR 529

Alanine Colorimetric/Fluorometric Assay Kit

K2205-100 100 assays
EUR 502

Citrate Colorimetric/Fluorometric Assay Kit

K2207-100 100 assays
EUR 544

Calpain Activity Fluorometric Assay Kit

K240-100
EUR 588

Proteasome Activity Fluorometric Assay Kit

K245-100
EUR 479

Lysozyme Activity Assay Kit (Fluorometric)

K236-100
EUR 490

Neuraminidase Activity Fluorometric Assay Kit

K2230-100 100 assays
EUR 599

Glucose Uptake Fluorometric Assay Kit

K2212-100 100 assays
EUR 1198

Caspase-3 Fluorometric Assay Kit

K105-100
EUR 479

Caspase-8 Fluorometric Assay Kit

K112-100
EUR 479

Caspase-6 Fluorometric Assay Kit

K114-100
EUR 430

Caspase-2 Fluorometric Assay Kit

K116-100
EUR 463

Caspase-9 Fluorometric Assay Kit

K118-100
EUR 468

GST Fluorometric Activity Assay Kit

K2105-100 100 assays
EUR 502

PicoProbe? ADP Assay Kit (Fluorometric)

K211-100
EUR 582

Pyruvate Colorimetric/Fluorometric Assay Kit

K2119-100 100 assays
EUR 614

Adipogenesis Colorimetric/Fluorometric Assay Kit

K2120-100 100 assays
EUR 447

Fructose Colorimetric/Fluorometric Assay Kit

K2124-100 100 assays
EUR 502

Ethanol Colorimetric/Fluorometric Assay Kit

K2125-100 100 assays
EUR 586

Galactose Colorimetric/Fluorometric Assay Kit

K2126-100 100 assays
EUR 502

Lactose Colorimetric/Fluorometric Assay Kit

K2129-100 100 assays
EUR 502

Creatinine Colorimetric/Fluorometric Assay Kit

K2130-100 100 assays
EUR 447

Maltose Colorimetric/Fluorometric Assay Kit

K2132-100 100 assays
EUR 502

Creatine Colorimetric/Fluorometric Assay Kit

K2137-100 100 assays
EUR 502

Sarcosine Colorimetric/Fluorometric Assay Kit

K2138-100 100 assays
EUR 502

Glycogen Colorimetric/Fluorometric Assay Kit

K2143-100 100 assays
EUR 614

Calpain Activity Fluorometric Assay Kit

K2062-100 100 assays
EUR 627

Aspartate Colorimetric/Fluorometric Assay Kit

K2082-100 100 assays
EUR 502

Phosphatidylcholine Colorimetric/Fluorometric Assay Kit

K2086-100 100 assays
EUR 502

PLTP Activity Fluorometric Assay Kit

K2087-100 100 assays
EUR 669

CETP Activity Fluorometric Assay Kit

K2089-100 100 assays
EUR 725

Glucose Colorimetric/Fluorometric Assay Kit

K2091-100 100 assays
EUR 502

Lactate Colorimetric/Fluorometric Assay Kit

K2092-100 100 assays
EUR 614

Proteasome Activity Fluorometric Assay Kit

K2096-100 100 assays
EUR 502

GST Fluorometric Activity Assay Kit

K260-100
EUR 468

HDAC3 Activity Fluorometric Assay Kit

K343-100
EUR 479

HDAC8 Activity Fluorometric Assay Kit

K348-100
EUR 490

Phospholipid Assay Kit (Colorimetric/Fluorometric)

K351-100
EUR 550

ADP Colorimetric/Fluorometric Assay Kit

K355-100
EUR 582

FAD Colorimetric/Fluorometric Assay Kit

K357-100
EUR 512

Thrombin Activity Fluorometric Assay Kit

K373-100
EUR 697

Total Polyamine Assay Kit (Fluorometric)

K475-100
EUR 572

PicoProbeTM Methylglyoxal Assay Kit (Fluorometric)

K461-100
EUR 555

PicoProbe? Threonine Assay Kit (Fluorometric)

K463-100
EUR 610

HDAC6 Activity Assay Kit (Fluorometric)

K466-100
EUR 631

Glycerophosphorylcholine Assay Kit (Colorimetric/Fluorometric)

K433-100
EUR 566

PicoProbe? Phosphate Fluorometric Assay Kit

K419-100
EUR 446

PicoProbe? Glutamate Assay Kit (Fluorometric)

K413-100
EUR 566

Maltose Colorimetric/Fluorometric Assay Kit

K628-100
EUR 512

Fructose Colorimetric/Fluorometric Assay Kit

K619-100
EUR 501

Ethanol Colorimetric/Fluorometric Assay Kit

K620-100
EUR 561

Galactose Colorimetric/Fluorometric Assay Kit

K621-100
EUR 512

Lactose Colorimetric/Fluorometric Assay Kit

K624-100
EUR 512

Creatinine Colorimetric/Fluorometric Assay Kit

K625-100
EUR 468

Sucrose Colorimetric/Fluorometric Assay Kit

K626-100
EUR 501

Creatine Colorimetric/Fluorometric Assay Kit

K635-100
EUR 479

Sarcosine Colorimetric/Fluorometric Assay Kit

K636-100
EUR 479

PicoProbe? Lactate Fluorometric Assay Kit

K638-100
EUR 620

Glycogen Colorimetric/Fluorometric Assay Kit

K646-100
EUR 610

Starch Colorimetric/Fluorometric Assay Kit

K647-100
EUR 490

Adipogenesis Colorimetric/Fluorometric Assay Kit

K610-100
EUR 430

PicoProbe? Fructose Fluorometric Assay Kit

K611-100
EUR 533

Caspase-5 Fluorometric Assay Kit

K122-100
EUR 436

Caspase-1 Fluorometric Assay Kit

K110-100
EUR 479

HAT Activity Fluorometric Assay Kit

K334-100
EUR 539

Sirtuin Activity Assay Kit (Fluorometric)

K324-100
EUR 572

HDAC Activity Fluorometric Assay Kit

K330-100
EUR 490

DL-Serine Assay Kit (Fluorometric)

K743-100
EUR 691

Urokinase Activity Fluorometric Assay Kit

K728-100
EUR 544

Plasmin Activity Assay Kit (Fluorometric)

K381-100
EUR 457

PEP Colorimetric/Fluorometric Assay Kit

K365-100
EUR 631

Chymotrypsin Activity Assay Kit (Fluorometric)

K352-100
EUR 490

ATP Colorimetric/Fluorometric Assay Kit

K354-100
EUR 582

Chitotriosidase Activity Assay Kit (Fluorometric)

K512-100
EUR 620

?-Glucuronidase Activity Assay Kit (Fluorometric)

K514-100
EUR 620

Methyltransferase Activity Assay Kit (Fluorometric)

K521-100
EUR 566

Soluble Collagen Assay Kit (Fluorometric)

K532-100
EUR 620

Albumin (Albuminuria) Fluorometric Assay Kit

K550-100
EUR 523

Aspartate Colorimetric/Fluorometric Assay Kit

K552-100
EUR 490

Sphingomyelinase Activity Fluorometric Assay Kit

K574-100
EUR 457

Phosphatidylcholine Colorimetric/Fluorometric Assay Kit

K576-100
EUR 490

HDL Uptake Assay Kit (Fluorometric)

K586-100
EUR 909

Deubiquitinase Activity Assay Kit (Fluorometric)

K485-100
EUR 533

Glucose Colorimetric/Fluorometric Assay Kit

K606-100
EUR 512

Lactate Colorimetric/Fluorometric Assay Kit

K607-100
EUR 610

Neprilysin Activity Assay Kit (Fluorometric)

K487-100
EUR 610

Pyruvate Colorimetric/Fluorometric Assay Kit

K609-100
EUR 610

PicoProbe? Phosphoglucomutase Assay Kit (Fluorometric)

K770-100
EUR 751

DPP4 Activity Fluorometric Assay Kit

K779-100
EUR 544

Protease Activity Fluorometric Assay Kit

K781-100
EUR 387

Renin Activity Fluorometric Assay Kit

K800-100
EUR 523

PicoProbe? Formaldehyde Fluorometric Assay Kit

K805-100
EUR 408

Copper Detection Assay Kit (Fluorometric)

K899-100
EUR 457

Cell Transformation Assay Kit (Fluorometric)

K922-100
EUR 599

In this research, so as to set up protein-protein interplay assays mimicking a binding floor between Sin3B and REST, we chosen necessary amino acids from structural data of the PAH1/REST complicated after which tried to reconstitute it utilizing recombinant quick peptides derived from PAH1/REST. Initially, we validated whether or not biotinylated REST interacts with glutathione S-transferase (GST)-tagged PAH1 and whether or not one other PAH1 peptide (PAH1-FLAG) competitively binds with biotinylated REST utilizing floor plasmon resonance (SPR). We noticed a direct interplay and aggressive binding of two PAH1 peptides.

Secondly, so as to set up a high-throughput and high-dynamic-range assay, we utilized an simply carried out novel time-resolved fluorescence vitality switch (TR-FRET) assay, and intently monitored this interplay. Finally, we succeeded in establishing a novel high-quality TR-FRET assay and a novel interplay assay primarily based on SPR.

SARS-CoV-2 diagnosis: What is new?

How do tests that reveal the SARS-CoV-2 virus work?

Covid-19 diagnostic tests are an essential tool for monitoring the spread of the pandemic. The World Health Organization (WHO) has repeatedly asked health agencies to make coronavirus testing a top priority, but international response has been mixed.

Why does their use vary so much from one country to another?

Thanks to a combination of enabling regulations and logistical readiness, some countries, such as South Korea and Singapore, have been able to rapidly deploy massive test campaigns targeting thousands of individuals; but elsewhere, several countries have struggled to keep pace.

What are the new types of tests in preparation?

Meanwhile, in the United States, faced with delays of several weeks from hospitals and manufacturers, university research laboratories have developed their diagnostic tools to meet needs.

Test, instructions for use

Most Covid-19 tests are now performed on viral genetic material from samples from the nose or pharynx. They are based on a molecular biology tool designated by the acronym RT-PCR. PCR (for polymerase chain reaction) is a method of duplicating (or amplifying) a DNA sequence in very large numbers thanks to an enzyme, the polymerase. We can then analyze the DNA.

However, since the coronavirus genome is in the form of RNA, it must first be transformed into DNA, which another enzyme does, reverse transcriptase (RT).

Amplification starts from short sequences, added primers, complementary to the sequence to be duplicated. However, PCR can only detect the virus when it is present, and is of no use when the epidemic is resolved. What is more, it sometimes produces false positives when the reagents (in particular the primers and the products necessary for the duplication of DNA) are contaminated.

Laboratories around the world quickly adapted their RT-PCR tests to SARS-CoV-2, by designing appropriate primers, complementary to various fragments of the genetic sequence of the virus.

Which countries have been reactive?

Several countries have been able to test very large numbers of people (see figure below). South Korea reacted when the first cases appeared at the end of January by deploying large quantities of rapid tests and then monitoring those in contact with those who had tested positive. Regulations promulgated after the Middle East respiratory syndrome (MERS) epidemic in 2015 (with 186 cases and 35 deaths, South Korea was the second most affected country after Saudi Arabia which counted 688 cases and 282 deaths) allowed rapid release of a version of the WHO test, and four companies produced enough to test up to 10,000 people per day.

In this way, explains Angela Rasmussen of Columbia University in New York, the South Korean authorities were able to identify the slightly ill and asymptomatic people and prevent them from spreading the virus. “The country has not had to take the drastic social distancing measures as in other countries,” she added.

As for Singapore, the city-state developed a test as soon as the coronavirus appeared in China, explains Vernon Lee, of the Singapore Ministry of Health, and was very early in battle order to track down the cases. Hospital laboratories were quickly given the green light to use other authorized PCR tests, provided that the results of the first cohort were validated by a national laboratory. They also focused the tests on the most essential cases such as patients with pneumonia or people at high risk, for example elderly people.

College of public health and occupational physicians
-Singapore-

Essential logistics were installed after the appearance in 2003 of another coronavirus, the SARS-Cov: it notably provides sufficient capacities in laboratories, trained personnel, reagents…

“In Singapore, we are ready and have ” a medical and hospital system strengthened since the SARS episode. It’s not something we created because of the Covid-19, ”

Vernon Lee.

The latecomers

Health experts have criticized the United States for its slow response to the pandemic, in particular the low availability of tests and their slow implementation. According to specialists, these failures allowed the virus to spread without being detected and imposed strict social distancing measures to contain it.

US health officials have admitted their fault. At a congressional hearing on March 12, the director of the National Institute of Allergies and Infectious Diseases (NIAID), Anthony Fauci, said that the country “is unable” to test the population and was not in able to meet demand for testing.

Kenneth Bernard, a former adviser to several US presidents on biodefense, said a coordinator or a White House office responsible for responding to the pandemic could have facilitated communication between the agencies and drawn up a plan to intensify the tests. But the person who held the office left President Donald Trump’s National Security Council … in May 2018.

“We had a problem with the scale. It is one thing to do a benchmark test at the CDC (Center for Disease Control and Prevention), but another to do millions of them, “warns Kenneth Bernard.

Rigid regulations for new diagnostic tests have been an additional barrier. Initially, the only approved American test was created by the CDC, but it was found to be defective. And only public health services were allowed to use it. The Food and Drug Administration (FDA) did not relax these rules until the end of February and did not allow private labs to test until mid-March. It was only on the 21st that the US authorities authorized a rapid test that did not require samples to be sent to a laboratory. It should be ready soon.

With the federal response long overdue, the virology laboratories at the University of Washington in Seattle organized the first major national testing operation. The researchers adapted the WHO protocol to work with the reagents and platforms they had on hand. Dozens of other laboratories and research consortia have followed suit.

“The federal government made the decision to severely limit access [to the tests] at first,” said Joshua Sharfstein, a former FDA official. “If you could go back and tell the FDA in mid-January that you’re really going to need a million tests soon enough, they would have chosen a different strategy. “

What about serological tests?

One of the main goals is to develop a serological test, which is one that can detect past viral infections by looking for antibodies that a formerly infected person has produced to fight the virus. Such a test would reveal the extent of viral spread in a population and would provide useful public health information.

“For the moment, it is clear that we are only seeing the tip of the iceberg: patients so severely affected that they must be hospitalized or even receive intensive care there,” explains Robert Garry, virologist at Tulane University, in New Orleans, Louisiana. “What is worrying is that there are a lot of patients with little or even asymptomatic disease outside. “

Several groups, including that of Robert Garry, are working on carrying out such a serological test. Another team, including researchers from Icahn School of Medicine at Mount Sinai Hospital in New York, developed one that she describes in a prepublication, not peer reviewed, posted on medRxiv on March 18. “We don’t see any obstacle to carrying out these tests, only a few adjustments,” says Robert Garry.

A team in Singapore used serological tests to trace contacts of patients, but at the time, the method used had not been validated for clinical use. “We think this is the first time in the world that this type of testing has been used in this context,” said Danielle Anderson, virologist at the faculty of medicine at Duke and Singapore Universities, in Singapore, during a press conference in February.

Make way for innovation

Research groups led by two of CRISPR’s leading specialists, the tool that makes it easy to modify an organism’s genome, are each working on tests that leverage this gene editing technique to improve testing.

First, at the University of Washington, virologist Keith Jerome and his colleagues improved the SHERLOCK test (for specific high sensitivity enzymatic reporter unlocking) developed by Feng Zhang at the Massachusetts Institute of Technology. The latter said he had sent some 1,600 test kits to ten laboratories around the world.

Next, Mammoth Biosciences, a California-based biotechnology company co-founded by Jennifer Doudna of the University of California at Berkeley, is working on another CRISPR-based method called DETECTR to detect SARS-CoV-2.

Both techniques use CRISPR’s ability to recognize and cut specific genetic sequences. Here, he also cuts a reporter molecule added to the reaction, which relatively quickly reveals the presence of viral genetic material.

“Whenever we are faced with an epidemic, we are late because we do not have rapid diagnostic tools to detect and identify the new organism in question,” said Charles Chiu of the University of California at San Francisco, who works with Mammoth Biosciences. “The main advantages of CRISPR are its specificity and speed, a test which can be carried out in 5 to 10 minutes. “

Robert Garry, at Tulane, is optimistic about such advances. “It is a powerful technique. I’ve seen it work with the Zika virus and a few other viruses, “he says. “If anyone can find a way to lessen the impact of the Covid-19, let’s do it. “